ATE236975T1 - Haarnadelförmiges ribozym - Google Patents

Haarnadelförmiges ribozym

Info

Publication number
ATE236975T1
ATE236975T1 AT93914943T AT93914943T ATE236975T1 AT E236975 T1 ATE236975 T1 AT E236975T1 AT 93914943 T AT93914943 T AT 93914943T AT 93914943 T AT93914943 T AT 93914943T AT E236975 T1 ATE236975 T1 AT E236975T1
Authority
AT
Austria
Prior art keywords
polyribonucleotide
ribozyme
hairpin
shaped
forth
Prior art date
Application number
AT93914943T
Other languages
English (en)
Inventor
Eiko Otsuka
Makoto Koizumi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Application granted granted Critical
Publication of ATE236975T1 publication Critical patent/ATE236975T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin

Landscapes

  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT93914943T 1992-07-02 1993-07-02 Haarnadelförmiges ribozym ATE236975T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP17570692 1992-07-02
JP23691692 1992-09-04
PCT/JP1993/000907 WO1994001549A1 (fr) 1992-07-02 1993-07-02 Ribozyme bouclee en epingle a cheveux

Publications (1)

Publication Number Publication Date
ATE236975T1 true ATE236975T1 (de) 2003-04-15

Family

ID=26496887

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93914943T ATE236975T1 (de) 1992-07-02 1993-07-02 Haarnadelförmiges ribozym

Country Status (8)

Country Link
US (1) US5631115A (de)
EP (1) EP0653488B1 (de)
AT (1) ATE236975T1 (de)
AU (1) AU672018B2 (de)
CA (1) CA2139411A1 (de)
DE (1) DE69332856D1 (de)
NO (1) NO311258B1 (de)
WO (1) WO1994001549A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19532651A1 (de) * 1995-09-05 1997-03-06 Aloysius Dr Dickgreber Mittel zur therapeutischen Anwendung bei HIV-Infektionen
US5888767A (en) * 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
US5885806A (en) * 1995-11-28 1999-03-23 The Johns Hopkins University School Of Medicine Methods to prepare conditionally replicating viral vectors
US6274369B1 (en) * 1996-02-02 2001-08-14 Invitrogen Corporation Method capable of increasing competency of bacterial cell transformation
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
JP5305553B2 (ja) 2000-10-12 2013-10-02 ユニバーシティー オブ ロチェスター 癌細胞の増殖を阻害する組成物
EP1572168B1 (de) 2002-02-06 2010-05-26 Vicor Technologies, Inc. Anti-infarkt-moleküle
EP1534729A2 (de) * 2002-02-26 2005-06-01 University of Utah Research Foundation Mit bluthochdruck und virusknospung assoziierte nedd4l-varianten
US20040005546A1 (en) * 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
US20050287648A1 (en) 2002-08-05 2005-12-29 University Of Rochester Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
CA2507863A1 (en) * 2002-12-04 2004-06-17 Algos Therapeutics, Inc. Methods and materials for modulating trpm2
BRPI0606791A2 (pt) 2005-02-02 2010-02-09 The Uab Research Foundation métodos de reverter ou prevenir a resistência de uma célula a um agonista do receptor da morte, de triar uma célula quanto a um biomarcador da resistência a um agonista do receptor da morte, de monitorar a resistência a um agonista do receptor da morte em um indivìduo, de induzir seletivamente a apoptose em uma célula alvo expressando um receptor da morte, de tratar de um indivìduo com cáncer, de tratar de um indivìduo com uma doença inflamatória ou autoimune, de bloquear a ligação da proteìna contendo card a um receptor da morte em uma célula, de bloquear a associação de um iap com o receptor da morte e de triar um modulador de uma proteìna contendo card, composição, ácido nucleico isolado, vetor, célula, e, polipeptìdeo isolado
EP2551282A3 (de) 2005-03-23 2013-02-13 Genmab A/S Antikörper gegen CD38 zur Behandling von multiplem Myelom
US7476733B2 (en) 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
FR2887259B1 (fr) * 2005-06-21 2007-09-14 Agronomique Inst Nat Rech CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES
AU2006302245A1 (en) * 2005-10-06 2007-04-19 Emthrax, Llc Methods and compositions relating to anthrax spore glycoproteins as vaccines
EP1934348B1 (de) * 2005-10-11 2018-05-02 Ben-Gurion University Of The Negev Research And Development Authority Zusammensetzung zum silencing der expression von vdac1 und verwendungen davon
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2395076A1 (de) 2005-10-14 2011-12-14 MUSC Foundation For Research Development Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
EP2066812A4 (de) 2006-09-21 2010-04-28 Univ Rochester Zusammensetzungen und verfahren in zusammenhang mit proteinverschiebungstherapie für myotone dystrophie
EP2078079B1 (de) * 2006-11-01 2011-05-04 The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ-12-lipoxygenase
WO2008136852A2 (en) 2006-11-01 2008-11-13 University Of Rochester Methods and compositions related to the structure and function of apobec3g
JP2010512327A (ja) 2006-12-11 2010-04-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 病的血管形成および脈管透過性の処置用の組成物および方法
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2010070380A2 (en) * 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
US20110262395A1 (en) 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
WO2011031974A1 (en) 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
EP2986317A4 (de) 2013-04-15 2016-10-05 Yeda Res & Dev Hemmung von rip-kinasen zur behandlung lysosomaler speicherkrankheiten
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポe模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
US10723794B2 (en) 2015-03-18 2020-07-28 University Of South Carolina Anti-CcL8 antibodies and uses thereof
EP3496736A4 (de) 2016-08-03 2020-05-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gegen tlr9 gerichtete therapeutika
WO2019051355A1 (en) 2017-09-08 2019-03-14 Ohio State Innovation Foundation NEW MICROARN INHIBITOR THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
US12492245B2 (en) 2021-09-21 2025-12-09 University Of South Carolina Anti-CCL8 antibodies and treatment of lung injury by CCL8 inhibition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE115999T1 (de) * 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
CA1340323C (en) * 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences

Also Published As

Publication number Publication date
NO945103L (no) 1995-03-02
DE69332856D1 (de) 2003-05-15
NO311258B1 (no) 2001-11-05
CA2139411A1 (en) 1994-01-20
NO945103D0 (no) 1994-12-30
EP0653488B1 (de) 2003-04-09
AU4513093A (en) 1994-01-31
AU672018B2 (en) 1996-09-19
US5631115A (en) 1997-05-20
EP0653488A1 (de) 1995-05-17
EP0653488A4 (de) 1997-01-15
WO1994001549A1 (fr) 1994-01-20

Similar Documents

Publication Publication Date Title
AU672018B2 (en) Looped, hairpin ribozyme
TR200001892T2 (tr) Monomer cinsi ensülin analogları ve bunların kullanımı.
ES2130428T3 (es) Cristales de insulina asp-b28.
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
PT1143937E (pt) O e declinio rapido das concentracoes eficazes de droga no plasma formulacoes de libertacao controlada com um arranque rapid
EA200200616A1 (ru) Химические производные и их применение в качестве антителомеразного агента
TR200003113T2 (tr) 3-(amino- veya aminoalkil) piridinon türevleri ve bunların HIV bağımlı hastalıkların tedavisinde kullanılması.
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
PT693924E (pt) Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
PT1001775E (pt) Medicamento contendo ioimbina e arginina para tratamento de disfuncao erectil
ES2124861T3 (es) Derivados de aminoacidos y su utilizacion como inhibidores de la encefalinasa.
ATE291586T1 (de) Humanes antibiotisches protein
DE60125232D1 (de) Kleines säurelösliches sporenprotein und seine verwendungen
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
GR3032224T3 (en) Therapeutic agent for threatened abortion.
PL365292A1 (en) Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
ATE28188T1 (de) Antikonvulsive mittel.
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
CY1106702T1 (el) Χρηση ενος συνδυασμου μιας πουρινης και ενος παραγοντα δοτη μονοξειδιου του αζωτου για την προληψη ή την αγωγη γενετησιων δυσλειτουργιων
DE3879985D1 (de) Anticonvulsive agenzien.
CY1106235T1 (el) Χρηση της l-καρνιτινης ως σταθepοποιητικου παραγοντα πρωτεϊνων
DE3788888D1 (de) Perhydrothiazepin- und Perhydroazepinderivate, ihre Herstellung und ihre therapeutische Verwendung.
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
ES2053834T3 (es) Un metodo para la preparacion de una sustancia terapeutica.
ES2185147T3 (es) Nuevos usos medicos del orosomucoide.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties